Form 4: OrbiMed Advisors Acquires Warrants in Corvus Pharmaceuticals, Limits Exercise to Under 10% Ownership

OrbiMed Advisors LLC acquired pre-funded and common warrants in Corvus Pharmaceuticals on May 6, 2024, with exercise limitations to maintain ownership below 9.99%.

Summary

• OrbiMed Advisors LLC, along with OrbiMed Capital GP V LLC, filed a Form 4 detailing the acquisition of pre-funded and common warrants in Corvus Pharmaceuticals, Inc. on May 6, 2024.
• The acquired securities are held by OrbiMed Private Investments V, LP (OPI V), with OrbiMed Capital GP V LLC (GP V) as the general partner and OrbiMed Advisors LLC as the managing member.
• The pre-funded warrants allow the holder to purchase 1,444,085 shares of common stock at an exercise price of $0.0001 per share.
• The common warrants allow the holder to purchase 1,397,684 shares of common stock at an exercise price of $3.50 per share.
• Both the pre-funded and common warrants contain an exercise limitation (the 'Blocker') that prevents the holder from exercising the warrants if it would result in beneficial ownership exceeding 9.99% of the outstanding common stock.
• Due to the Blocker, the warrants are not presently exercisable.
• The warrants were issued at no additional consideration to OPI V in connection with its subscription of Pre-Funded Warrants for shares of the Issuer's Common Stock at a price of $1.7311.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing detailing warrant acquisitions. The exercise limitations introduce a slightly cautious element.

Positives

• The acquisition of warrants indicates a continued investment and interest in Corvus Pharmaceuticals by OrbiMed Advisors.

Negatives

• The exercise limitations on the warrants could restrict OrbiMed's ability to fully capitalize on potential gains in Corvus Pharmaceuticals' stock price.

Risks

• The 'Blocker' provision could limit OrbiMed's influence and control over Corvus Pharmaceuticals.
• The value of the warrants is dependent on the future performance of Corvus Pharmaceuticals' stock.

Future Outlook

The document does not contain specific forward-looking statements regarding Corvus Pharmaceuticals' future performance, but the warrant acquisition suggests a continued interest from OrbiMed.

Industry Context

Form 4 filings are standard disclosures for significant shareholders and insiders, providing transparency into their transactions and ownership positions. OrbiMed's investment reflects ongoing interest in the biotechnology sector.

Comparison to Industry Standards

• Similar investment firms like Baker Bros. Advisors and RA Capital Management also frequently utilize warrants and options in their biotech investments.
• The 9.99% ownership limitation is a common strategy to avoid triggering certain regulatory thresholds and reporting requirements.

Stakeholder Impact

• Shareholders: The warrant acquisition could be viewed positively, indicating continued institutional interest.
• Employees: No direct impact is apparent from this filing.
• Customers: No direct impact is apparent from this filing.
• Suppliers: No direct impact is apparent from this filing.
• Creditors: No direct impact is apparent from this filing.

Key Dates